E. Mercier

H. Lazar1
E. Rabelo1
Y.-A. Que1
J.-J. Rouby1
1H. Lazar
1E. Rabelo
1Y.-A. Que
1J.-J. Rouby
Learn More
The fully human anti-lipopolysaccharide (LPS) immunoglobulin M (IgM) monoclonal antibody panobacumab was developed as an adjunctive immunotherapy for the treatment of O11 serotype Pseudomonas aeruginosa infections. We evaluated the potential clinical efficacy of panobacumab in the treatment of nosocomial pneumonia. We performed a post-hoc analysis of a(More)
Experiments were conducted to quantify the effect of several variables on the mortality of insects exposed to an anoxic treatment in order to generate a model linking mortality to these variables. This study aims to explore the possible interest of using such a model to determine the characteristics of treatment (especially duration) needed to guarantee(More)
  • 1